Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
Maurie
M
Markman
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000379:methods* / Q000592:standards; D018572:Disease-Free Survival; D023381:Endpoint Determination / Q000379:methods* / Q000592:standards; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents